The cost-effectiveness of long-term post-treatment peer recovery support services in the United States

被引:0
|
作者
de Martell, Sierra Castedo [1 ,2 ]
Moore, Margaret Brannon [2 ]
Wang, Hannah [2 ]
Steiker, Lori Holleran
Wilkerson, J. Michael [2 ]
Ranjit, Nalini [2 ]
Mccurdy, Sheryl A. [2 ]
Brown, H. Shelton [2 ]
机构
[1] Lighthouse Inst, Chestnut Hlth Syst, Bloomington, IL USA
[2] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Houston, TX USA
基金
美国国家卫生研究院;
关键词
Peer recovery support services; cost-effectiveness analysis; cost-effectiveness calculator; recovery community organizations; recovery community centers; peer coaching; SUBSTANCE-ABUSE TREATMENT; HEALTH;
D O I
10.1080/00952990.2024.2406251
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Peer recovery support services (PRSS) have been widely adopted across a variety of settings, but little is known about their economic impact.Objectives: To conduct a cost-effectiveness analysis of long-term, PRSS delivered after specialty substance use disorder (SUD) treatment (post-treatment), and to describe the development of a free, web-based cost-effectiveness calculator based on this analysis.Methods: Using publicly available data from a variety of sources, post-treatment PRSS were compared to specialty SUD treatment from the societal (broad perspective including costs like participant time) and health systems perspectives (only costs borne by health system), and in terms of quality-adjusted life years (QALYs) added and people in recovery. Whenever possible, 2019 data were used to avoid the impacts of COVID-19. Standard willingness-to-pay thresholds and additional treatment episode cost ($17,203.74) were used. One-way and probabilistic sensitivity analyses were conducted. Two recovery community organizations (RCOs) were involved in model refinement and calculator development in 2022.Results: Post-treatment PRSS were cost-effective to all thresholds and perspectives: $5,898.60 per QALY and $10,562.08 per person in recovery from the health system perspective, and $3,421.58 per QALY and $6,126.72 per person in recovery from the societal perspective, and post-treatment PRSS remained cost-effective across a variety of conditions in the sensitivity analyses. A cost-effectiveness calculator was developed from the analysis and is available at https://go.uth.edu/cea.Conclusions: In light of finding PRSS cost-effective, the expansion of PRSS across the US should continue, and may be aided by using the cost-effectiveness calculator to estimate tailored results for a specific program.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Long-Term Cost-Effectiveness of a Diabetes Risk Score
    Sullivan, Sean D.
    Pollock, Richard
    Garrison, Louis P.
    Rinde, Harald
    Kolberg, Janice A.
    DIABETES, 2009, 58 : A44 - A44
  • [22] Long-term cost-effectiveness of clopidogrel in STEMI patients
    Zhang, Zefeng
    Kolm, Paul
    Mosse, Frederique
    Jackson, Joseph
    Zhao, Liping
    Weintraub, William S.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2009, 135 (03) : 353 - 360
  • [23] The long-term effects and cost-effectiveness of success for all
    Borman, GD
    Hewes, GM
    EDUCATIONAL EVALUATION AND POLICY ANALYSIS, 2002, 24 (04) : 243 - 266
  • [24] LONG-TERM COST-EFFECTIVENESS OF LASMIDITAN, UBROGEPANT AND RIMEGEPANT FOR TREATMENT OF ACUTE MIGRAINE
    Touchette, D.
    Atlas, S. J.
    Agboola, F. O.
    Joshi, M.
    Lee, T. A.
    Chapman, R. H.
    Pearson, S. D.
    Rind, D. M.
    VALUE IN HEALTH, 2020, 23 : S261 - S261
  • [25] Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US
    O'Day, Ken
    Rajagopalan, Krithika
    Meyer, Kellie
    Pikalov, Andrei
    Loebel, Antony
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2013, 5 : 459 - 470
  • [26] Long-term treatment costs and cost-effectiveness of restoration repair versus replacement
    Kanzow, Philipp
    Krois, Joachim
    Wiegand, Annette
    Schwendicke, Falk
    DENTAL MATERIALS, 2021, 37 (06) : E375 - E381
  • [27] Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States
    Chen, Jing Voon
    Klein, Timothy M.
    Nesheim, Jeffrey
    Mudd, Paul N., Jr.
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 1092 - 1100
  • [28] The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States
    Tremblay, Gabriel
    Dolph, Mike
    Roy, Anuja Nidumolu
    Said, Qayyim
    Forsythe, Anna
    CLINICAL THERAPEUTICS, 2020, 42 (05) : 860 - +
  • [29] Tranexamic acid in the treatment of post-partum hemorrhage in the united states: a cost-effectiveness analysis
    Sudhof, Leanna S.
    Shainker, Scott A.
    Einerson, Brett D.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2019, 220 (01) : S491 - S491
  • [30] Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States A Cost-Effectiveness Analysis
    Neilan, Anne M.
    Landovitz, Raphael J.
    Le, Mylinh H.
    Grinsztejn, Beatriz
    Freedberg, Kenneth A.
    McCauley, Marybeth
    Wattananimitgul, Nattanicha
    Cohen, Myron S.
    Ciaranello, Andrea L.
    Clement, Meredith E.
    Reddy, Krishna P.
    Hyle, Emily P.
    Paltiel, A. David
    Walensky, Rochelle P.
    ANNALS OF INTERNAL MEDICINE, 2022, 175 (04) : 479 - +